Amneal Pharmaceuticals (AMRX) is trading at new 5-year highs with strong technical momentum. AMRX has gained 69% over the past year. Shares maintain a 100% “Buy” technical opinion on Barchart. Analyst sentiment is positive, with multiple “Strong Buy” ratings and price targets as high as $15. Today’s Featured Stock Valued at $3.98 billion, Amneal Pharmaceuticals (AMRX) is an integrated specialty pharmaceutical company. It focuses on developing, manufacturing, and distributing generic, brand, and ...

Core Insights - Teva Pharmaceutical Industries Limited (NYSE:TEVA) is identified as one of the best growth stocks under $25, with a price target raised from $22 to $24 by Bank of America Securities while maintaining a Buy rating [1] Financial Performance - Teva's management anticipates full-year revenue between $16.8 billion and $17.2 billion, indicating a year-over-year increase of 2% to 4%, which aligns with the consensus estimate of $16.901 billion [3] Market Trends - The analyst from Bank of America previewed EPS estimates for commercial-stage biotech companies, indicating no major surprises expected for Q3 in the sector based on pricing volume trends for key drugs [2]